1. [CASE 1 — QUESTION 1] A 58-year-old man weighing 125 kg (height 178 cm, ideal body weight [IBW] 78 kg) presents to the emergency department with septic shock — blood pressure 82/46 mmHg requiring norepinephrine, heart rate 124 bpm, temperature 39.6°C, and lactate 5.1 mmol/L. He has no known antibiotic allergies. Blood cultures are drawn and empiric therapy with piperacillin-tazobactam is started. Given the severity of his presentation and concern for multidrug-resistant gram-negative organisms, the team plans to add gentamicin using extended-interval dosing at 7 mg/kg. The clinical pharmacist recommends calculating the dose based on adjusted body weight rather than total body weight. What is the correct adjusted body weight and gentamicin dose for this patient, and what is the pharmacokinetic rationale for this weight adjustment?

• A) Total body weight of 125 kg should be used because aminoglycosides distribute into all tissues proportionally; the correct dose is 875 mg; using a lower adjusted weight would result in subtherapeutic peak concentrations and failure to achieve the Cmax/MIC ratio needed for concentration-dependent killing against gram-negative organisms in a critically ill patient.
• B) Adjusted body weight (AdjBW) = IBW + 0.4 × (TBW − IBW) = 78 + 0.4 × (125 − 78) = 78 + 18.8 = 96.8 kg, rounded to approximately 97 kg; the correct dose is approximately 679 mg (7 mg/kg × 97 kg); this correction is required because aminoglycosides are hydrophilic and distribute primarily into extracellular fluid rather than adipose tissue, so total body weight overestimates the volume of distribution and risks toxicity, while IBW alone underestimates the partial contribution of excess lean tissue and extracellular fluid.
• C) Ideal body weight of 78 kg should be used without correction because aminoglycosides are entirely confined to the plasma compartment in critically ill patients; the correct dose is 546 mg; any upward correction above IBW in a critically ill patient increases nephrotoxicity risk disproportionately because critical illness reduces renal aminoglycoside clearance.
• D) Lean body weight calculated by the Janmahasatian formula supersedes adjusted body weight for critically ill obese patients; the 0.4 correction factor is only valid in ambulatory patients; in critically ill patients with vasopressor-dependent septic shock, a correction factor of 0.6 should be used to account for third-space fluid expansion that adds to the extracellular distribution volume.
• E) No weight correction is needed for gentamicin dosing in obese patients because the Hartford nomogram automatically adjusts for body composition when the timed serum level is obtained and plotted; the nomogram's pharmacokinetic modeling corrects for volume of distribution differences by using the observed drug concentration rather than estimated weight-based parameters.

2. [CASE 1 — QUESTION 2] Continuing with the same patient. The gentamicin infusion is administered over 60 minutes. Eight hours after the start of the infusion, a serum gentamicin level is drawn and returns at 2.4 mcg/mL. The pharmacist plots this on the Hartford nomogram. The point falls in the q36h zone. The intern asks what this result means and what dosing interval should be used going forward.

• A) The 8-hour level of 2.4 mcg/mL falling in the q36h zone indicates that gentamicin is accumulating dangerously and the drug should be immediately discontinued; levels above 2 mcg/mL at 8 hours indicate nephrotoxic accumulation regardless of the nomogram zone.
• B) The 8-hour level of 2.4 mcg/mL falling in the q36h zone indicates that the peak concentration was insufficient to achieve the Cmax/MIC target; the nomogram result means the dose of 7 mg/kg should be increased to 10 mg/kg while keeping the interval at every 24 hours.
• C) The 8-hour level of 2.4 mcg/mL falling in the q36h zone is uninterpretable because the Hartford nomogram requires levels drawn at exactly 6 hours or exactly 12 hours after infusion completion; a level drawn at 8 hours after infusion start (approximately 7 hours after completion of a 60-minute infusion) does not fall within a validated sampling window.
• D) The 8-hour level of 2.4 mcg/mL falling in the q36h zone indicates that this patient has reduced gentamicin clearance relative to the q24h zone patient; the Hartford nomogram assigns a q36h interval, meaning the next dose should be given 36 hours after the first dose rather than 24 hours; the dose of 7 mg/kg per injection remains unchanged — only the interval is adjusted to account for slower clearance and prevent trough accumulation.
• E) The 8-hour level of 2.4 mcg/mL falling in the q36h zone confirms excellent pharmacokinetics; the q36h zone on the Hartford nomogram is the optimal zone indicating that the Cmax/MIC ratio is maximized while trough concentrations will fall to zero by 36 hours; no adjustment is needed and the current 24-hour interval should be continued.

3. [CASE 1 — QUESTION 3] Continuing with the same patient. The patient improves hemodynamically over the following 48 hours and is weaned off vasopressors. Gentamicin is continued on the q36h schedule alongside piperacillin-tazobactam. On day 6, the morning creatinine is 1.9 mg/dL, up from a baseline of 1.0 mg/dL on admission. The patient is euvolemic and non-oliguric. Urinalysis shows granular casts and trace proteinuria. No new medications have been added.

• A) The creatinine rise to 1.9 mg/dL (90% increase from baseline) is consistent with aminoglycoside nephrotoxicity: gentamicin accumulates in proximal tubular cells via megalin-cubilin receptor-mediated endocytosis, generating reactive oxygen species that cause tubular cell death; the non-oliguric pattern and granular casts are characteristic of proximal tubular injury; serum creatinine may lag behind actual tubular damage by 24–48 hours; the appropriate response is to reassess the ongoing need for gentamicin in the context of now-available susceptibility data, and if combination therapy is no longer indicated, to discontinue gentamicin and monitor renal function daily.
• B) The creatinine rise is caused by piperacillin-tazobactam-induced acute interstitial nephritis, which commonly develops on days 5–7 of beta-lactam therapy; granular casts are characteristic of interstitial nephritis; gentamicin should be continued and piperacillin-tazobactam substituted with an alternative agent such as meropenem; aminoglycoside nephrotoxicity does not present as non-oliguric AKI with granular casts.
• C) The creatinine rise reflects the normal expected trajectory of critical illness-associated AKI from his original septic shock presentation; this pattern is not caused by gentamicin because the q36h schedule with Hartford nomogram guidance eliminates aminoglycoside nephrotoxicity risk; no medication changes are required and the team should optimize volume status and await spontaneous creatinine improvement.
• D) The creatinine rise indicates that the q36h dosing interval is too frequent for this patient; the Hartford nomogram level should be repeated and if it falls in the q48h zone, the interval extended; the mechanism is accumulation of gentamicin in the distal tubule rather than proximal tubule, which is why the pattern is non-oliguric and associated with granular casts rather than oliguria and red cell casts.
• E) The creatinine rise is caused by contrast-induced nephropathy from CT imaging performed during his septic workup; the 5–7 day latency between contrast exposure and creatinine rise is characteristic of contrast nephropathy in critically ill patients; gentamicin should be continued because aminoglycoside nephrotoxicity does not occur when peak concentrations are within the therapeutic range as confirmed by the Hartford nomogram.

4. [CASE 1 — QUESTION 4] Continuing with the same patient. Blood cultures from admission have returned growing Escherichia coli susceptible to piperacillin-tazobactam (MIC 8 mcg/mL), ceftriaxone, and gentamicin. The patient is now clinically stable — vasopressors have been discontinued, temperature is 37.2°C, and he is mentating normally. His creatinine remains elevated at 1.8 mg/dL. The team asks whether gentamicin should be continued.

• A) Gentamicin should be continued for a total of 14 days because randomized trials have demonstrated that 14 days of aminoglycoside combination therapy is required to prevent relapse of gram-negative bacteremia in obese patients, who have higher bacterial burdens due to impaired immune function associated with adiposity; de-escalating to beta-lactam monotherapy before day 14 is associated with increased bacteremia relapse rates in this population.
• B) Gentamicin should be continued alongside piperacillin-tazobactam for the full treatment course because susceptibility confirmation does not justify de-escalation when the patient has ongoing renal injury; continuing the combination is necessary to prevent emergence of piperacillin-tazobactam resistance during monotherapy in a patient with a compromised immune barrier from his obesity and critical illness.
• C) Gentamicin should be discontinued now: the clinical evidence base demonstrates that beta-lactam plus aminoglycoside combination therapy does not improve mortality compared to monotherapy for gram-negative bacteremia caused by susceptible organisms in patients who have achieved clinical stability; the original indication for aminoglycoside use — broad empiric coverage during septic shock — has resolved; continuing gentamicin in a patient with rising creatinine and confirmed susceptibility to piperacillin-tazobactam monotherapy adds nephrotoxicity risk without clinical benefit.
• D) Gentamicin should be continued at reduced dose to maintain some combination therapy benefit while minimizing nephrotoxicity; a 50% dose reduction from 7 mg/kg to 3.5 mg/kg every 36 hours preserves synergistic activity against E. coli while reducing renal tubular drug accumulation; once creatinine normalizes, the full dose can be resumed.
• E) The decision to discontinue gentamicin cannot be made on clinical grounds alone; the team must obtain repeat blood cultures, and gentamicin should be continued until two consecutive blood cultures drawn 48 hours apart are negative; bacteremia clearance confirmed by repeat cultures is the only valid endpoint for aminoglycoside de-escalation in gram-negative bacteremia.

5. [CASE 2 — QUESTION 1] A 32-year-old woman with cystic fibrosis (CF) — a genetic disorder caused by CFTR dysfunction impairing chloride transport and producing abnormally viscous secretions — is admitted for a pulmonary exacerbation. Her sputum cultures grow Pseudomonas aeruginosa susceptible to tobramycin (MIC 1 mcg/mL). She weighs 54 kg (IBW 55 kg) and has a serum creatinine of 0.7 mg/dL. The team starts tobramycin 7 mg/kg IV every 24 hours (378 mg per dose). A Hartford nomogram level is drawn 8 hours after the first infusion and returns at 1.6 mcg/mL, falling below the acceptable zone on the nomogram. Why is the standard 7 mg/kg extended-interval dose predictably inadequate in this patient?

• A) The standard dose is inadequate because CF causes progressive renal tubular damage that accelerates tobramycin elimination through an upregulated tubular secretion mechanism; the increased renal clearance depletes serum tobramycin concentrations faster than the normal glomerular filtration rate would predict, requiring higher doses to maintain therapeutic trough levels.
• B) The standard dose is inadequate because CFTR dysfunction causes hepatic enzyme induction that accelerates tobramycin metabolism through CYP3A4; aminoglycosides undergo significant hepatic first-pass metabolism in CF patients, substantially reducing systemic bioavailability; a higher IV dose compensates for the increased hepatic extraction ratio.
• C) The standard dose is inadequate because CF-associated pulmonary inflammation creates a drug sequestration compartment in airways that sequesters tobramycin away from the systemic circulation; the measured serum level of 1.6 mcg/mL is artificially low because the true peak concentration is trapped in bronchiectatic airways and not reflected in the serum level.
• D) The standard dose is inadequate because CF patients have markedly decreased volume of distribution due to muscle wasting and reduced lean body mass; the smaller extracellular fluid space produces higher than expected serum concentrations at standard doses, and the 1.6 mcg/mL level at 8 hours actually indicates toxicity risk rather than inadequacy; the dose should be reduced rather than increased.
• E) The standard dose is inadequate because CF patients have both a markedly increased volume of distribution from altered body composition and augmented renal clearance from enhanced glomerular filtration and tubular secretion; together these produce lower peak concentrations and faster drug elimination than expected at standard doses, causing the 8-hour level to fall below the Hartford nomogram acceptable zone; tobramycin doses of 8–10 mg/kg/day or higher are typically required in CF patients with frequent pharmacokinetic monitoring to individualize the regimen.

6. [CASE 2 — QUESTION 2] Continuing with the same patient. The tobramycin dose is increased to 9 mg/kg every 24 hours (486 mg), and a repeat pharmacokinetic level confirms adequate peak exposure. A pharmacy student on rotation asks the team why tobramycin was chosen over gentamicin for this patient's Pseudomonas aeruginosa infection. Which of the following correctly explains the pharmacological basis for tobramycin's preference over gentamicin for Pseudomonas aeruginosa?

• A) Tobramycin is preferred over gentamicin for Pseudomonas aeruginosa because tobramycin is not susceptible to inactivation by the PAO-1 acetyltransferase that Pseudomonas constitutively expresses; gentamicin is uniformly inactivated by this enzyme regardless of the specific isolate, making gentamicin predictably ineffective against all Pseudomonas infections while tobramycin retains reliable activity.
• B) Tobramycin is preferred over gentamicin for Pseudomonas aeruginosa because tobramycin achieves approximately two- to four-fold lower minimum inhibitory concentrations against this organism than gentamicin; this superior intrinsic potency translates into a higher Cmax/MIC ratio at equivalent doses, producing better concentration-dependent bactericidal activity; the lower MIC advantage is intrinsic to the drug-organism interaction and applies regardless of AME resistance status.
• C) Tobramycin is preferred over gentamicin for Pseudomonas aeruginosa because tobramycin penetrates Pseudomonas biofilm more effectively than gentamicin due to its smaller molecular weight, allowing it to reach bacteria within the biofilm matrix that are impermeable to gentamicin; this biofilm penetration advantage is particularly important in CF patients where chronic Pseudomonas colonization produces mature biofilms.
• D) Tobramycin is preferred over gentamicin for Pseudomonas aeruginosa because tobramycin undergoes slower renal elimination in Pseudomonas infections, producing sustained peak concentrations that extend the period during which the Cmax/MIC ratio exceeds 8–10; gentamicin is more rapidly eliminated during Pseudomonas infections due to Pseudomonas-produced enzymes that enhance gentamicin renal clearance.
• E) Tobramycin is preferred over gentamicin for Pseudomonas aeruginosa because tobramycin is immune to all AME variants expressed by Pseudomonas, including the AAC(3)-IIa enzyme that confers gentamicin resistance; amikacin shares this AME immunity with tobramycin; both agents retain activity against all Pseudomonas isolates regardless of AME carriage.

7. [CASE 2 — QUESTION 3] Continuing with the same patient. She responds well to IV tobramycin plus an antipseudomonal beta-lactam and is preparing for discharge. Her pulmonologist explains that she will need a long-term plan to suppress her chronic Pseudomonas aeruginosa colonization and reduce future exacerbation frequency. The team discusses inhaled tobramycin. Which of the following correctly describes the approved inhaled tobramycin formulations and the pharmacokinetic rationale that makes chronic inhaled suppression feasible where prolonged systemic therapy would not be?

• A) Inhaled tobramycin is administered as a continuous daily nebulization regimen without drug-free intervals because Pseudomonas airway biofilms require uninterrupted drug exposure to prevent regrowth during off-periods; the drug-free interval used in alternating monthly regimens allows biofilm reconstitution and is therefore pharmacodynamically inferior to continuous daily dosing.
• B) Inhaled tobramycin is administered as a once-weekly single dose because the prolonged tissue half-life of tobramycin in bronchiectatic airways exceeds 7 days, providing week-long bactericidal concentrations from a single inhalation; weekly dosing reduces the risk of adaptive resistance that would develop with more frequent inhalation schedules.
• C) Inhaled tobramycin is not an established therapy for CF; the correct chronic suppression strategy is alternating monthly courses of oral ciprofloxacin, which achieves adequate pulmonary Pseudomonas suppression with lower systemic toxicity than any inhaled aminoglycoside formulation; tobramycin is restricted to IV use for acute exacerbations only.
• D) Inhaled tobramycin is approved in two formulations — tobramycin inhalation solution (TIS) for nebulization and tobramycin inhalation powder (TIP) for dry powder inhaler delivery; both deliver very high drug concentrations directly to the airways with minimal systemic absorption because the polycationic drug is poorly absorbed across respiratory epithelium; this confines activity to the lung and avoids the nephrotoxicity and ototoxicity that would preclude the years-long treatment courses required for chronic Pseudomonas suppression; inhaled tobramycin reduces exacerbation frequency and slows FEV1 decline in CF patients with chronic Pseudomonas colonization.
• E) Inhaled tobramycin provides its benefit through systemic rather than local drug delivery; after inhalation, tobramycin is absorbed across the respiratory epithelium and achieves serum concentrations equivalent to a low intravenous dose; the clinical benefit of inhaled tobramycin in CF therefore reflects systemic aminoglycoside exposure rather than local airway drug activity, and nephrotoxicity monitoring equivalent to intravenous therapy is required during inhaled courses.

8. [CASE 2 — QUESTION 4] Continuing with the same patient. She asks her pulmonologist how the inhaled tobramycin works differently from the IV tobramycin she just received in hospital, and whether she still needs to worry about her kidneys and hearing during the inhaled course. Which of the following best explains the pharmacokinetic difference between inhaled and intravenous tobramycin and correctly characterizes the systemic toxicity risk of the inhaled route?

• A) Inhaled tobramycin achieves bactericidal drug concentrations in airway secretions that are many-fold above the Pseudomonas MIC because the drug is deposited directly at the site of infection; systemic absorption across the respiratory epithelium is minimal because tobramycin's polycationic character makes it poorly permeable across biological membranes; as a result, serum tobramycin concentrations during inhaled therapy are very low, and the nephrotoxicity and ototoxicity risks that limit systemic therapy are not clinically significant concerns during standard inhaled courses — serial monitoring of serum creatinine and audiometry equivalent to IV therapy is not required.
• B) Inhaled tobramycin achieves its effect through the same pharmacokinetic mechanism as IV tobramycin — both routes produce equivalent systemic drug concentrations; the inhaled route simply avoids the discomfort of IV cannulation; because systemic exposure is equivalent, nephrotoxicity and ototoxicity monitoring requirements are identical for inhaled and IV tobramycin courses.
• C) Inhaled tobramycin is a prodrug formulation that is converted to active tobramycin by Clara cell esterases in the airway epithelium; the conversion is incomplete systemically, producing lower serum concentrations than IV tobramycin; because the nephrotoxic metabolite is generated only in the airway, renal toxicity is eliminated but cochlear hair cells can still accumulate the active metabolite through endolymph transport, so audiometric monitoring remains mandatory.
• D) Inhaled tobramycin achieves its effect by producing very high systemic concentrations through rapid respiratory absorption; the high serum Cmax achieved via the inhaled route is actually higher than that achieved with IV dosing because the pulmonary vasculature bypasses hepatic first-pass metabolism; this explains why ototoxicity risk with inhaled tobramycin exceeds that of IV tobramycin and audiometric monitoring every 2 weeks during the inhaled course is required.
• E) Inhaled tobramycin works by stimulating local airway macrophages to produce tobramycin-specific antibodies that opsonize Pseudomonas aeruginosa; the therapeutic benefit is immunological rather than direct bactericidal, explaining why airway drug concentrations are not required to exceed the Pseudomonas MIC and why systemic toxicity does not occur despite repeated monthly courses over many years.

9. [CASE 3 — QUESTION 1] A 71-year-old man with a history of type 2 diabetes and chronic kidney disease stage 3 (baseline creatinine 1.5 mg/dL, eGFR 44 mL/min) presents with fever, new mitral regurgitation murmur, and embolic phenomena. Blood cultures grow Enterococcus faecalis susceptible to ampicillin. Gentamicin MIC is 8 mcg/mL (below the high-level aminoglycoside resistance threshold of 500 mcg/mL). The cardiology fellow proposes ampicillin 2g IV every 4 hours plus gentamicin for 6 weeks. The pharmacist asks which gentamicin dosing approach and therapeutic drug monitoring targets will be used if the team chooses this regimen. Which of the following correctly states the appropriate dosing strategy and TDM targets for gentamicin in enterococcal endocarditis synergy?

• A) Extended-interval dosing with Hartford nomogram monitoring should be used: a single level at 6–14 hours after the first 5–7 mg/kg dose is plotted on the nomogram to determine the q24h, q36h, or q48h interval; peak targets for endocarditis synergy are the same as for gram-negative bacteremia (6–10 mcg/mL) because bactericidal killing against enterococci requires the same Cmax/MIC ratio as gram-negative infections.
• B) Multiple-daily dosing should be used with peaks targeted at 15–20 mcg/mL to achieve bactericidal enterococcal killing, with troughs below 8 mcg/mL; these are the amikacin MDD targets that apply to all aminoglycosides including gentamicin when used for endocarditis; higher peaks are required for enterococcal synergy than for gram-negative bacteremia because enterococci have higher gentamicin MICs.
• C) Multiple-daily dosing should be used: gentamicin is given at 1 mg/kg every 8 hours (approximately 3 mg/kg/day); TDM targets are peak concentrations of 3–5 mcg/mL (lower than gram-negative bacteremia targets because synergy is achieved at lower concentrations when a cell wall-active agent permeabilizes the enterococcal cell wall) and trough concentrations below 2 mcg/mL, ideally below 1 mcg/mL, to minimize nephrotoxicity during the prolonged course.
• D) No therapeutic drug monitoring is required for gentamicin synergy in endocarditis; fixed weight-based dosing at 1 mg/kg every 8 hours is standard and has been validated without monitoring in multiple endocarditis trials; TDM adds cost without reducing nephrotoxicity rates when the synergy dose regimen is followed precisely.
• E) Extended-interval dosing is contraindicated in endocarditis because continuous bactericidal drug concentrations above the MBC (minimum bactericidal concentration) are required throughout the cardiac cycle to prevent bacterial embolization; multiple-daily dosing at gram-negative bacteremia peak targets (6–10 mcg/mL) must be used with trough levels maintained above 2 mcg/mL to ensure continuous bactericidal activity.

10. [CASE 3 — QUESTION 2] Continuing with the same patient. After hearing the TDM targets, the infectious disease consultant recommends against gentamicin synergy altogether and proposes ampicillin plus ceftriaxone instead. The fellow asks why ampicillin plus ceftriaxone is preferred over the classic ampicillin plus gentamicin regimen in this patient specifically.

• A) Ampicillin plus ceftriaxone is preferred because this patient's E. faecalis isolate has a gentamicin MIC of 8 mcg/mL, which exceeds the susceptibility breakpoint for gentamicin synergy of less than 4 mcg/mL; an MIC of 8 mcg/mL defines intermediate resistance to gentamicin synergy, and ampicillin plus ceftriaxone is the recommended alternative when gentamicin synergy is not microbiologically reliable.
• B) Ampicillin plus ceftriaxone is preferred because ceftriaxone achieves higher myocardial tissue concentrations than gentamicin at clinical doses, producing superior endocardial bactericidal killing in vegetations; gentamicin does not penetrate cardiac valve tissue in bactericidal concentrations at synergy dosing levels.
• C) Ampicillin plus ceftriaxone is preferred because this patient's diabetes increases the risk of gentamicin-induced ototoxicity specifically — diabetic patients have higher perilymph glucose concentrations that amplify aminoglycoside hair cell toxicity; ceftriaxone provides identical ototoxicity protection as a non-aminoglycoside alternative.
• D) Ampicillin plus ceftriaxone is preferred because ceftriaxone has direct intrinsic bactericidal activity against E. faecalis as monotherapy, making the combination more potent than ampicillin plus gentamicin; clinical trials demonstrate that the ceftriaxone component achieves bactericidal killing against enterococci independently of ampicillin, providing redundant bactericidal mechanisms that reduce treatment failure rates.
• E) Ampicillin plus ceftriaxone is preferred because clinical data including the PENTA trial demonstrated equivalent efficacy to ampicillin plus gentamicin for E. faecalis endocarditis with substantially less nephrotoxicity; this patient's pre-existing CKD stage 3 substantially amplifies his nephrotoxicity risk from a 6-week gentamicin synergy course, making the equally effective but renally safer ampicillin plus ceftriaxone combination the clearly preferred choice — avoiding aminoglycoside exposure eliminates cumulative proximal tubular toxicity risk in a patient with already-reduced renal reserve.

11. [CASE 3 — QUESTION 3] Continuing with the same patient. The team decides to proceed with ampicillin plus gentamicin against the consultant's recommendation, citing the classic regimen as established standard of care. Gentamicin is started at 1 mg/kg every 8 hours. On day 10, TDM results return: peak 4.2 mcg/mL (target 3–5 mcg/mL) and trough 2.8 mcg/mL (target below 2 mcg/mL, ideally below 1 mcg/mL). Creatinine has risen from 1.5 to 2.2 mg/dL. What is the clinical significance of the elevated trough and the appropriate management response?

• A) A trough of 2.8 mcg/mL is within acceptable limits for enterococcal endocarditis synergy because troughs below 4 mcg/mL are considered safe for the duration of endocarditis therapy; the creatinine rise from 1.5 to 2.2 mg/dL is expected and acceptable as a predictable pharmacological effect of prolonged synergy therapy that does not require any medication change.
• B) A trough of 2.8 mcg/mL exceeds the target of below 2 mcg/mL (ideally below 1 mcg/mL) and indicates that gentamicin is accumulating in the proximal tubular compartment via megalin-cubilin receptor-mediated endocytosis, driving the nephrotoxicity that has produced the creatinine rise from 1.5 to 2.2 mg/dL; the appropriate response is to extend the dosing interval (for example, to every 12 hours rather than every 8 hours) to allow trough concentrations to fall toward target, and to reassess daily whether continuing gentamicin is justified given the ongoing renal injury and the availability of the equally effective but renally safer ampicillin plus ceftriaxone alternative.
• C) A trough of 2.8 mcg/mL indicates that the gentamicin dose is too low rather than too high; troughs above 2 mcg/mL in endocarditis synergy indicate subtherapeutic dosing because adequate bactericidal penetration of cardiac vegetations requires trough concentrations above 2 mcg/mL throughout the dosing interval; the dose should be increased and the interval shortened to every 6 hours.
• D) A trough of 2.8 mcg/mL and creatinine rise to 2.2 mg/dL together indicate that this patient has developed HLAR during therapy; high-level aminoglycoside resistance causes drug accumulation by preventing intracellular uptake, producing elevated troughs; repeat susceptibility testing confirming HLAR should be ordered and gentamicin discontinued if confirmed.
• E) The trough of 2.8 mcg/mL is not clinically significant because trough concentrations for aminoglycosides reflect efficacy rather than toxicity; a trough above the minimum inhibitory concentration ensures sustained bactericidal activity throughout the dosing interval, which is the pharmacodynamic goal of endocarditis synergy therapy; the creatinine rise is unrelated to gentamicin and should be investigated for other causes.

12. [CASE 3 — QUESTION 4] Continuing with the same patient. On day 14, the patient reports new difficulty hearing high-pitched sounds. Audiometry confirms bilateral high-frequency sensorineural hearing loss at 4–8 kHz bilaterally, with normal low-frequency thresholds. He asks whether his hearing will recover when the gentamicin is stopped. Which of the following best explains the mechanism of his hearing loss, the anatomical pattern, and the prognosis?

• A) The high-frequency hearing loss is caused by gentamicin-induced endolymphatic hydrops from accumulation of drug in inner ear endolymph beyond the stria vascularis reabsorption capacity; endolymphatic pressure normalizes when gentamicin is discontinued, and hearing thresholds return to baseline within 3–6 months in most patients with drug-free intervals longer than 8 weeks.
• B) The high-frequency hearing loss is caused by gentamicin-induced demyelination of the high-frequency auditory nerve fibers in the spiral ganglion; gentamicin preferentially damages high-frequency fibers because they have lower conduction velocity and are therefore more vulnerable to oxidative demyelination; hearing partially recovers over 12–18 months as remyelination occurs.
• C) The hearing loss is not caused by gentamicin because gentamicin is preferentially vestibulotoxic rather than cochleotoxic; high-frequency sensorineural hearing loss is inconsistent with gentamicin ototoxicity, which characteristically presents as oscillopsia and balance dysfunction rather than audiometric hearing loss; audiometry should be repeated and the hearing loss attributed to age-related presbycusis.
• D) The high-frequency sensorineural hearing loss results from gentamicin accumulation in cochlear outer hair cells, where the drug generates reactive oxygen species activating apoptotic pathways that destroy the outer hair cells of the basal cochlear turn responsible for high-frequency processing; while gentamicin is more commonly vestibulotoxic than cochleotoxic, cochlear injury can occur, particularly with prolonged courses and elevated cumulative exposure; the prognosis for recovery is poor because mammalian cochlear outer hair cells cannot regenerate after aminoglycoside-induced destruction.
• E) The hearing loss is reversible because gentamicin-induced outer hair cell inhibition is pharmacodynamically reversible — gentamicin binds competitively to cochlear outer hair cell mechanotransduction channels and dissociates when drug is discontinued, restoring normal mechanoelectrical transduction within weeks; patients who stop gentamicin promptly after onset of hearing symptoms recover full hearing in over 90% of cases within 6 months.

13. [CASE 4 — QUESTION 1] A 45-year-old man is on day 8 of mechanical ventilation in the surgical ICU following a Whipple procedure complicated by anastomotic leak. He develops ventilator-associated pneumonia. Bronchoalveolar lavage cultures grow Pseudomonas aeruginosa with the following susceptibilities: gentamicin MIC 32 mcg/mL (resistant), tobramycin MIC 16 mcg/mL (resistant), amikacin MIC 8 mcg/mL (susceptible), meropenem MIC 1 mcg/mL (susceptible), cefepime MIC 4 mcg/mL (susceptible). The team starts meropenem plus amikacin. The pharmacist explains the resistance pattern before writing the amikacin order. Which of the following best explains the mechanism responsible for gentamicin and tobramycin resistance with preserved amikacin susceptibility?

• A) This resistance pattern — gentamicin and tobramycin resistant, amikacin susceptible — is the clinical signature of aminoglycoside-modifying enzyme (AME) resistance: AMEs encoded on mobile plasmids modify specific hydroxyl or amino groups on gentamicin and tobramycin, abolishing ribosomal binding; amikacin escapes inactivation because its 1-N-acyl substituent creates steric hindrance that prevents most AMEs from accessing the equivalent modification sites on the amikacin ring structure, preserving its activity against AME-carrying isolates.
• B) This resistance pattern is explained by 16S rRNA methyltransferase activity: the armA gene product has methylated the aminoglycoside binding site on 16S rRNA but has not yet methylated all available ribosomal subunits; gentamicin and tobramycin bind to methylated ribosomes and are inactivated, while amikacin's larger molecular size allows it to bind to partially methylated ribosomes that have insufficient methylation density to block amikacin binding; over time, complete methylation will eliminate amikacin susceptibility as well.
• C) This resistance pattern is explained by porin downregulation: the isolate has lost OprD and OprF, preventing gentamicin and tobramycin from entering the periplasmic space via EDP-I; amikacin enters through an alternative porin channel (OprM) that remains expressed; meropenem and cefepime susceptibility is preserved because they enter through routes independent of OprD in this isolate.
• D) This resistance pattern is explained by MexXY-OprM efflux pump upregulation pumping gentamicin and tobramycin out of the periplasm; amikacin is not a substrate for MexXY-OprM because its 1-N-acyl substituent increases its molecular weight above the efflux channel substrate size limit; amikacin should therefore be effective regardless of MexXY-OprM expression level.
• E) This resistance pattern cannot be explained by known resistance mechanisms and likely represents mixed culture contamination with a gentamicin-resistant non-Pseudomonas organism; any mechanism capable of inactivating gentamicin and tobramycin would necessarily inactivate amikacin; the susceptibility testing should be repeated with pure culture before amikacin is administered.

14. [CASE 4 — QUESTION 2] Continuing with the same patient. The pharmacist writes the amikacin order at 15 mg/kg every 24 hours extended-interval dosing. A pharmacy student asks why the amikacin dose is 15 mg/kg when gentamicin would have been dosed at 7 mg/kg — and whether the higher amikacin dose is intended to overwhelm the AME resistance that inactivates gentamicin. Which of the following correctly explains why amikacin requires a higher mg/kg dose than gentamicin and whether this higher dose is an AME-overcoming strategy?

• A) The higher amikacin dose is an AME-overcoming strategy: at 15 mg/kg, serum amikacin concentrations exceed the AME enzyme maximum velocity (Vmax), saturating all expressed AME copies before they can modify the drug; once AME saturation is achieved, residual unmodified amikacin reaches the ribosome in bactericidal concentrations; gentamicin at 7 mg/kg does not achieve sufficient concentration to saturate AMEs, which is why it fails in AME-carrying isolates.
• B) The higher amikacin dose is required because amikacin has a higher volume of distribution than gentamicin due to its 1-N-acyl substituent increasing lipophilicity; the larger distribution volume requires a proportionally higher dose to achieve the same serum peak concentration as gentamicin; the pharmacodynamic target Cmax/MIC of 8–10 is the same for both agents.
• C) The higher amikacin dose reflects amikacin's generally higher MIC against gram-negative organisms compared to gentamicin — not an AME-overcoming strategy; amikacin's activity against this AME-carrying isolate is structural, not dose-dependent, deriving from the 1-N-acyl steric protection; the 15 mg/kg dose is required to achieve a Cmax/MIC ratio above 8–10 against amikacin's higher baseline MICs, just as 7 mg/kg achieves the same Cmax/MIC target against gentamicin's lower baseline MICs against susceptible organisms.
• D) The higher amikacin dose is required because amikacin undergoes partial renal tubular secretion that reduces systemic exposure below what glomerular filtration alone would achieve; a higher dose compensates for this tubular secretion loss; gentamicin is not secreted by tubular cells and therefore achieves higher serum concentrations per milligram than amikacin at equivalent weight-based doses.
• E) The higher amikacin dose is a precautionary measure reflecting amikacin's narrower therapeutic window compared to gentamicin; at the 7 mg/kg dose used for gentamicin, amikacin produces supratherapeutic serum concentrations due to its greater potency; 15 mg/kg was derived by reducing the gentamicin-equivalent dose by a safety correction factor that accounts for amikacin's greater cochleotoxicity relative to its nephrotoxicity potential.

15. [CASE 4 — QUESTION 3] Continuing with the same patient. On day 14, repeat BAL cultures again grow Pseudomonas aeruginosa, but the susceptibility profile has changed: gentamicin MIC >256 mcg/mL (resistant), tobramycin MIC >256 mcg/mL (resistant), amikacin MIC >256 mcg/mL (resistant), meropenem MIC 8 mcg/mL (now resistant). The microbiologist requests urgent genotypic testing. What resistance mechanism has most likely emerged to explain the new amikacin resistance with MIC above 256 mcg/mL, and what does the simultaneous meropenem resistance suggest?

• A) The new amikacin resistance with MIC above 256 mcg/mL has emerged from a hyperproducing AAC(6')-Ib variant that evolved during amikacin therapy to overcome the steric protection of the 1-N-acyl substituent through increased enzyme production; the simultaneous meropenem resistance reflects OprD porin loss, which is a separate chromosomal mutation unrelated to the aminoglycoside resistance; these two mechanisms arose independently.
• B) The new amikacin resistance with MIC above 256 mcg/mL reflects progressive MexXY-OprM efflux pump upregulation during amikacin therapy; initially the pump was partially expressed and insufficient to efflux amikacin, but selective pressure has increased pump expression beyond the threshold required to exclude amikacin; the simultaneous meropenem resistance reflects MexAB-OprM upregulation triggered by the same beta-lactam selection pressure.
• C) The new amikacin resistance with MIC above 256 mcg/mL reflects mutation in the penicillin-binding protein gene that cross-links the aminoglycoside ring structure through a previously uncharacterized mechanism; simultaneous meropenem resistance reflects mutation in the same PBP gene that confers carbapenem resistance; both resistances are governed by the same mutational event.
• D) The new amikacin resistance with MIC above 256 mcg/mL reflects accumulation of multiple AME variants acquired through sequential horizontal plasmid transfer during the treatment course; five or more AME variants acting cooperatively can overcome amikacin's 1-N-acyl steric protection; the simultaneous meropenem resistance reflects acquisition of a serine carbapenemase (KPC) on a separate plasmid transferred from another ICU patient.
• E) The new amikacin resistance with MIC above 256 mcg/mL most likely reflects acquisition of an RMTase gene such as armA or rmtB, which methylates the 16S rRNA aminoglycoside binding site — a target-modification mechanism that overcomes amikacin's 1-N-acyl structural protection against AMEs because the protection is only relevant against drug-modifying enzymes, not against a chemically altered ribosomal binding site; the simultaneous meropenem resistance raises the alarm for co-carriage of an RMTase and a carbapenemase (such as NDM or VIM) on the same mobile plasmid, representing one of the most clinically alarming gram-negative resistance combinations with severely limited remaining therapeutic options.

16. [CASE 4 — QUESTION 4] Continuing with the same patient. Genotypic testing confirms the isolate carries both armA and blaNDM on the same plasmid. The infectious disease consultant calls an urgent meeting. Which of the following best describes the clinical management priorities and epidemiological implications of this finding?

• A) The armA-blaNDM co-location is clinically significant only for this patient; horizontal plasmid transfer between Pseudomonas strains is extremely rare in ICU settings and does not pose a meaningful risk to other patients; the priority is optimizing therapy for this patient using polymyxin B monotherapy, which retains full activity against all RMTase-NDM co-expressing organisms regardless of resistance mechanism.
• B) The armA-blaNDM co-location on a single mobile plasmid is one of the most clinically alarming resistance combinations in gram-negative bacteriology: a single horizontal transfer event can simultaneously confer pan-aminoglycoside resistance plus carbapenem resistance to any recipient gram-negative organism; treatment options are severely limited and require urgent infectious disease and clinical microbiology consultation to identify remaining susceptibilities (potentially cefiderocol, aztreonam-avibactam, plazomicin depending on susceptibility testing); infection control escalation — including contact precautions, enhanced environmental cleaning, and screening of ward contacts — is urgently required to prevent plasmid dissemination to other patients and organisms.
• C) The armA-blaNDM co-location is treated identically to standard carbapenem-resistant Enterobacteriaceae (CRE) infections; the aminoglycoside resistance component adds no management complexity because aminoglycosides are not recommended for CRE treatment; the priority is selecting a carbapenem-sparing regimen using ceftazidime-avibactam, which retains full activity against all NDM-expressing organisms.
• D) The armA-blaNDM co-location is best managed by empirically adding all available antibiotics simultaneously — carbapenems at high dose, colistin, cefiderocol, and aztreonam — in a combination strategy that statistically maximizes the probability of including at least one active agent; the probability that all agents are simultaneously resistant is too low to justify withholding any available antibiotic.
• E) The armA-blaNDM finding in Pseudomonas aeruginosa does not require infection control escalation because Pseudomonas is already subject to contact precautions in all ICU patients; the plasmid cannot transfer to other gram-negative organisms because Pseudomonas conjugative plasmids are species-restricted and cannot be taken up by Enterobacteriaceae; management focuses on amikacin dose escalation to 30 mg/kg to overcome RMTase methylation through concentration-driven competitive displacement of the methyl group from 16S rRNA.

17. [CASE 5 — QUESTION 1] A 29-year-old woman at 24 weeks gestation presents with high fever, rigors, and flank pain. Urinalysis shows pyuria and bacteriuria. Blood cultures are drawn. She has a penicillin allergy described as anaphylaxis. The emergency physician considers gentamicin for empiric gram-negative coverage, noting it is often cited as an option in penicillin-allergic patients. A clinical pharmacist is consulted and explains several important limitations before gentamicin is ordered. The first concerns the spectrum of aminoglycoside activity. Which of the following correctly identifies which categories of organisms are NOT covered by gentamicin regardless of in vitro susceptibility results, and explains the mechanism responsible for this gap?

• A) Gentamicin does not cover gram-positive cocci because gram-positive organisms lack the lipopolysaccharide (LPS) outer membrane required for EDP-I electrostatic binding; without EDP-I, the drug cannot initiate the entry sequence and has no access to the inner membrane transport mechanism; gram-positive bacteremia and UTI requires a separate agent even when gentamicin is included.
• B) Gentamicin does not cover intracellular pathogens such as Chlamydia trachomatis or Listeria monocytogenes because aminoglycosides cannot penetrate host cell membranes; in a pregnant patient, intracellular pathogens causing pyelonephritis require a different antibiotic class; gentamicin covers only extracellular gram-negative organisms.
• C) Gentamicin does not cover fungi because aminoglycosides bind exclusively to the 16S rRNA of prokaryotic 30S ribosomal subunits and fungi possess only eukaryotic 18S and 28S ribosomal subunits; fungal UTI in pregnancy requires an antifungal agent; fungal infection should be in the differential in a pregnant patient with UTI that does not respond to gentamicin within 48 hours.
• D) Gentamicin has no useful activity against obligate anaerobes regardless of in vitro susceptibility testing results: obligate anaerobes lack an electron transport chain and cannot generate the proton motive force (PMF) required to drive EDP-II active transport of aminoglycosides across the inner membrane; without intracellular drug accumulation, ribosomal binding cannot occur; although pyelonephritis is not typically caused by obligate anaerobes, this mechanistic limitation must be understood to avoid using aminoglycosides in mixed infections with an anaerobic component.
• E) Gentamicin does not cover Pseudomonas aeruginosa in pregnant patients because the fetal-placental unit concentrates gentamicin through active transport, reducing serum free drug concentrations below the Pseudomonas MIC threshold; Pseudomonas coverage requires tobramycin in pregnancy because tobramycin does not undergo placental concentration.

18. [CASE 5 — QUESTION 2] Continuing with the same patient. The pharmacist's second concern is aminoglycoside safety in pregnancy. She explains that gentamicin crosses the placenta and has documented fetal risks that must be weighed against the benefit of treatment. Which of the following correctly describes the primary fetal risk associated with aminoglycoside use in pregnancy and how it should factor into the clinical decision?

• A) The primary fetal risk of aminoglycoside use in pregnancy is sensorineural hearing loss in the neonate: aminoglycosides cross the placenta and accumulate in fetal cochlear outer hair cells via the same megalin-cubilin uptake mechanism that causes maternal cochleotoxicity; fetal cochlear hair cells, which are actively developing during the second trimester, may be particularly vulnerable; while aminoglycosides are not absolutely contraindicated in pregnancy, this ototoxicity risk means that when a safe and effective alternative exists — such as a third-generation cephalosporin (e.g., ceftriaxone) with careful skin testing or graded challenge to address the penicillin allergy history — it should be preferred over gentamicin; aminoglycoside use in pregnancy should be reserved for situations where alternatives are genuinely unavailable or clinically inferior.
• B) The primary fetal risk of aminoglycoside use in pregnancy is teratogenicity during the first trimester — gentamicin is an FDA category X agent that causes neural tube defects through inhibition of fetal ribosomal protein synthesis during neurulation; at 24 weeks gestation, the neural tube has closed and this teratogenicity risk no longer applies; gentamicin is therefore safe to use from the second trimester onward without any fetal safety concern.
• C) The primary fetal risk of aminoglycoside use in pregnancy is uteroplacental vasoconstriction: gentamicin blocks Ca2+ channels in uterine vascular smooth muscle, reducing placental blood flow and causing fetal growth restriction; this risk is dose-dependent and can be prevented by calcium gluconate pretreatment before each gentamicin dose throughout the course.
• D) Aminoglycosides have no documented fetal risks in human pregnancy; the fetal toxicity concerns derive entirely from animal teratogenicity studies using doses 100-fold above human therapeutic concentrations; at clinical doses in humans, placental barrier function prevents aminoglycoside transfer to the fetus; gentamicin can be used freely in pregnancy without any additional fetal safety monitoring.
• E) The primary fetal risk of aminoglycoside use in pregnancy is aminoglycoside-induced suppression of fetal immune system development: gentamicin crosses the placenta and accumulates in fetal lymphoid tissue where it inhibits ribosomal protein synthesis in rapidly dividing lymphocyte precursors; the resulting neonatal immunodeficiency manifests as recurrent infections in the first year of life; this risk is irreversible and requires neonatal immunological evaluation if gentamicin was used during the second or third trimester.

19. [CASE 5 — QUESTION 3] Continuing with the same patient. The team decides to use gentamicin given no safe alternative is immediately available. They plan to use extended-interval dosing with Hartford nomogram monitoring. The pharmacist cautions about a specific limitation of the Hartford nomogram that applies to this patient. Which of the following correctly identifies the Hartford nomogram limitation relevant to this patient?

• A) The Hartford nomogram is not validated in patients receiving concomitant beta-lactam antibiotics because beta-lactams competitively displace aminoglycosides from the megalin-cubilin receptor, altering renal elimination kinetics and producing unreliable nomogram levels; all patients receiving combination therapy require formal pharmacokinetic modeling rather than nomogram-based interval assignment.
• B) The Hartford nomogram is not validated in patients with a body mass index above 30 kg/m2 because obesity alters the pharmacokinetic assumptions underlying the nomogram's concentration-time curves; the pharmacist should use adjusted body weight for dosing and formal pharmacokinetic modeling for interval assignment rather than the nomogram in any obese patient regardless of pregnancy status.
• C) The Hartford nomogram is explicitly not validated in pregnant patients; pregnancy alters aminoglycoside pharmacokinetics through increased GFR, expanded extracellular fluid volume, and altered renal tubular function — changes that systematically alter the concentration-time relationship underlying the nomogram's zone assignments; interval assignment based on the Hartford nomogram in a pregnant patient may be unreliable, and individualized pharmacokinetic monitoring using formal modeling or frequent serum levels is more appropriate.
• D) The Hartford nomogram is not validated for gentamicin doses below 7 mg/kg; in pregnant patients, gentamicin is typically dosed at 3–4 mg/kg to minimize fetal exposure, and this dose falls below the nomogram's validated range, making the zone assignments inapplicable; the Hartford nomogram can only be used when the full 7 mg/kg dose is administered regardless of patient population.
• E) The Hartford nomogram is not validated in patients under 30 years of age because young patients have higher GFR than the reference population used to develop the nomogram, causing all levels to fall in the q24h zone regardless of actual drug clearance; young pregnant women invariably receive q24h dosing from nomogram assessment even when their rapidly increasing GFR from pregnancy warrants q12h dosing for adequate Cmax/MIC achievement.

20. [CASE 5 — QUESTION 4] Continuing with the same patient. Blood cultures return growing Escherichia coli susceptible to ceftriaxone (MIC 0.25 mcg/mL), gentamicin (MIC 0.5 mcg/mL), and trimethoprim-sulfamethoxazole. The allergy team is consulted regarding the penicillin allergy. They document a low cross-reactivity risk between penicillins and third-generation cephalosporins and confirm that ceftriaxone can be used safely given the documented anaphylaxis was to a penicillin-class drug and the structures of the side chains differ. Which of the following represents the most appropriate definitive management of this patient's E. coli bacteremic pyelonephritis?

• A) Gentamicin should be continued as the definitive agent because it has the lowest MIC against this isolate (0.5 mcg/mL) and concentration-dependent killing with Cmax/MIC above 8–10 provides the most rapid bacterial eradication; ceftriaxone has a higher MIC (0.25 mcg/mL is still susceptible but a 2-fold higher value than gentamicin) and should be used only as a backup if gentamicin nephrotoxicity develops.
• B) Trimethoprim-sulfamethoxazole should be used as definitive therapy because it is the only oral agent available, and oral therapy is preferred over intravenous therapy for all gram-negative bacteremia to avoid line-associated complications; gentamicin and ceftriaxone should both be discontinued in favor of oral TMP-SMX step-down.
• C) Gentamicin plus ceftriaxone combination should be continued for the full treatment course because bacteremic pyelonephritis in pregnancy is a high-risk infection requiring combination therapy throughout; de-escalating to ceftriaxone monotherapy in a pregnant patient increases relapse risk because monotherapy cannot maintain bactericidal concentrations against E. coli in both the renal parenchyma and the bloodstream simultaneously.
• D) Gentamicin should be continued for at least 7 days because aminoglycosides have superior renal tissue penetration compared to cephalosporins and therefore achieve higher drug concentrations in the renal cortex where pyelonephritis is located; achieving high renal cortical drug concentrations is more important for pyelonephritis cure than serum MIC-based susceptibility testing.
• E) Ceftriaxone should be used as the definitive agent: it is susceptible (MIC 0.25 mcg/mL), clinically proven effective for gram-negative bacteremia and pyelonephritis, does not carry the fetal ototoxicity risk of continued aminoglycoside exposure, and does not require the pharmacokinetic monitoring complexity of gentamicin in a pregnant patient; once ceftriaxone safety is confirmed by the allergy team, switching from gentamicin to ceftriaxone eliminates aminoglycoside-related fetal risk, nephrotoxicity risk, and pharmacokinetic monitoring burden while providing equivalent clinical efficacy for this susceptible E. coli infection.

21. [CASE 6 — QUESTION 1] A 66-year-old man undergoes emergency sigmoid colectomy for a perforated diverticular abscess with fecal peritonitis. Intraoperative cultures show heavy mixed growth of gram-negative enteric organisms and Bacteroides fragilis. Postoperatively, the surgical team orders metronidazole plus gentamicin, explaining that metronidazole covers the anaerobes and gentamicin covers the gram-negative aerobes. The infectious disease consultant reviews the regimen and raises a concern about the gentamicin. Why does gentamicin fail to provide reliable gram-negative coverage in this peritoneal infection environment?

• A) Gentamicin fails in this peritoneal environment because B. fragilis produces a broad-spectrum aminoglycoside-modifying enzyme (AME) that is secreted into the peritoneal exudate, inactivating gentamicin before it can reach gram-negative aerobic target organisms; the secreted AME diffuses through peritoneal fluid and confers passive resistance on otherwise susceptible organisms sharing the same space.
• B) Gentamicin fails because EDP-II inner membrane transport of aminoglycosides requires a proton motive force (PMF) generated by an active electron transport chain; in the anaerobic environment of the infected peritoneal cavity, even facultative gram-negative aerobes such as E. coli shift to anaerobic metabolism and reduce or abolish their PMF; without PMF-driven EDP-II transport, gentamicin cannot accumulate intracellularly in bactericidal concentrations at the infection site, even if the organisms appear susceptible on in vitro aerobic testing.
• C) Gentamicin fails in this environment because the low pH of the peritoneal abscess cavity protonates the polycationic aminoglycoside, neutralizing its charge and preventing EDP-I electrostatic binding to LPS; without EDP-I outer membrane interaction, the drug cannot initiate the entry sequence; the pH-dependent inactivation renders all aminoglycosides ineffective in any infected body cavity regardless of aerobic or anaerobic conditions.
• D) Gentamicin fails because metronidazole inhibits the bacterial electron transport chain as part of its own bactericidal mechanism against anaerobes, and this PMF-collapsing effect extends to all organisms in the peritoneal cavity including the gram-negative aerobes; metronidazole and gentamicin are therefore pharmacodynamically antagonistic — metronidazole's mechanism directly blocks the PMF that gentamicin requires for EDP-II transport.
• E) Gentamicin is fully effective in the peritoneal environment and the consultant's concern is unwarranted; in vitro susceptibility testing performed under standard aerobic conditions is the correct predictor of in vivo activity for gram-negative organisms in any body cavity; the distinction between aerobic and anaerobic infection environments does not affect aminoglycoside pharmacodynamics because EDP-II transport is driven by pH gradients rather than electron transport chain activity.

22. [CASE 6 — QUESTION 2] Continuing with the same patient. A medical student asks the consultant to explain the two-stage energy-dependent entry mechanism of aminoglycosides and how each stage relates to the clinical failure of gentamicin in this patient's peritoneal infection. Which of the following correctly describes both stages and correctly identifies which stage fails in the anaerobic peritoneal environment?

• A) EDP-I is PMF-driven active transport across the outer bacterial membrane; EDP-II is electrostatic binding of the polycationic aminoglycoside to LPS with divalent cation displacement; EDP-I fails in the anaerobic environment because the PMF required for outer membrane transport collapses under anaerobic conditions; EDP-II is not affected because LPS electrostatic interaction does not require energy.
• B) EDP-I and EDP-II are both PMF-dependent steps occurring at the outer membrane and inner membrane respectively; both fail simultaneously in the anaerobic peritoneal environment; without either stage, no aminoglycoside reaches the periplasmic space, so the issue is complete exclusion of drug from the gram-negative cell before any transport step occurs.
• C) EDP-I is passive diffusion through outer membrane porins that requires no energy; EDP-II is ribosomal binding at the 16S rRNA decoding site that requires ATP hydrolysis for conformational binding; EDP-II fails in the anaerobic environment because ATP depletion in anaerobic metabolism prevents the energy-requiring step of ribosomal binding; EDP-I is unaffected because passive diffusion does not require metabolic energy.
• D) EDP-I involves electrostatic binding of the polycationic aminoglycoside to the negatively charged lipopolysaccharide of the gram-negative outer membrane, displacing Mg2+ and Ca2+ to disrupt outer membrane integrity and allow drug access to the inner membrane — this step does not require the electron transport chain and can occur in anaerobic conditions; EDP-II is active transport of aminoglycosides across the inner membrane into the cytoplasm, driven by the PMF generated by the electron transport chain — this step fails in obligate anaerobes and in facultative anaerobes operating anaerobically because without the electron transport chain there is no PMF to drive inner membrane transport; EDP-II failure prevents intracellular accumulation and abolishes bactericidal activity.
• E) EDP-I requires ATP hydrolysis by an ABC-type inner membrane transporter to pull aminoglycosides through the outer membrane by active chelation of LPS-bound drug; EDP-II is passive equilibration of drug between the periplasm and cytoplasm driven by the electrochemical gradient established by EDP-I; EDP-I fails in the anaerobic environment because ATP synthesis is impaired under anaerobic conditions, preventing the active outer membrane transport step.

23. [CASE 6 — QUESTION 3] Continuing with the same patient. The medical student asks a follow-up question: "If gentamicin did manage to get inside an aerobic gram-negative bacterium in this patient's peritoneum, what would happen next — and why can the same sequence never occur in Bacteroides fragilis even if trace drug did enter the cell?" Which of the following correctly describes the self-amplifying killing cycle in susceptible gram-negative bacteria and explains why it cannot be initiated in Bacteroides?

• A) In susceptible gram-negative bacteria, intracellular gentamicin binds the 16S rRNA decoding site of the 30S ribosomal subunit, causing mRNA misreading and production of aberrant proteins; these abnormal proteins insert into the inner membrane, creating channels that dramatically increase membrane permeability to aminoglycosides — initiating a self-amplifying cycle of increasing drug influx, worsening protein mistranslation, and accelerating membrane disruption that produces irreversible bactericidal killing; in Bacteroides fragilis, this cycle cannot be initiated because the drug cannot accumulate intracellularly through EDP-II in the first place — without intracellular drug, no ribosomal binding occurs, no aberrant proteins are produced, and the self-amplifying cycle has no starting point regardless of the drug's chemical properties.
• B) In susceptible gram-negative bacteria, intracellular gentamicin initiates killing by activating the bacterial SOS DNA repair response; the SOS response amplifies drug uptake by upregulating outer membrane porins and increases inner membrane permeability through RecA-mediated lipid remodeling; in Bacteroides fragilis, the SOS response cannot be activated because obligate anaerobes lack the RecA protein, preventing the self-amplifying killing cycle from engaging.
• C) In susceptible gram-negative bacteria, gentamicin kills by forming stable covalent bonds with the 16S rRNA decoding site, permanently inactivating the ribosome; the self-amplifying feature refers to the fact that each inactivated ribosome releases free gentamicin that diffuses to adjacent ribosomes, sequentially inactivating the entire ribosomal pool; in Bacteroides fragilis, this self-amplifying ribosomal cascade cannot occur because B. fragilis ribosomes have a constitutive methylation of the decoding site that prevents gentamicin binding at any intracellular concentration.
• D) In susceptible gram-negative bacteria, gentamicin initiates killing by blocking the bacterial electron transport chain at complex I, collapsing the PMF and preventing ATP synthesis; cell death results from energy depletion rather than ribosomal disruption; the self-amplifying aspect reflects increasing PMF collapse driving progressively deeper ATP depletion; in Bacteroides fragilis, blocking complex I cannot occur because B. fragilis lacks complex I, meaning gentamicin has no respiratory chain target.
• E) In susceptible gram-negative bacteria, gentamicin initiates the killing cascade by activating bacterial autolytic enzymes (muramidases) that degrade peptidoglycan from within; the self-amplifying cycle reflects progressive cell wall destruction that increases outer membrane permeability, allowing more drug entry; in Bacteroides fragilis, this pathway fails because B. fragilis produces a peptidoglycan-degrading inhibitor protein that prevents gentamicin-induced autolysis activation.

24. [CASE 6 — QUESTION 4] Continuing with the same patient. The infectious disease consultant recommends changing the antibiotic regimen. Intraoperative cultures have grown E. coli (susceptible to multiple agents including ceftriaxone and piperacillin-tazobactam) and Bacteroides fragilis (susceptible to metronidazole). Which of the following represents the most appropriate definitive antibiotic regimen for this patient's fecal peritonitis?

• A) Continue metronidazole plus gentamicin but increase the gentamicin dose to 10 mg/kg to overcome the PMF-dependent transport limitation; higher peak concentrations increase the passive driving force for aminoglycoside diffusion across the inner membrane independent of the PMF, providing bactericidal concentrations even in the anaerobic peritoneal environment.
• B) Discontinue metronidazole and gentamicin; start fluconazole plus daptomycin; fecal peritonitis invariably involves fungal co-infection requiring antifungal prophylaxis, and daptomycin provides superior gram-negative peritoneal penetration compared to aminoglycosides; fluconazole-daptomycin is the current Surgical Infection Society preferred regimen for fecal peritonitis.
• C) Replace gentamicin with an agent whose activity does not depend on PMF-driven transport and which covers gram-negative aerobes reliably in mixed infection environments: piperacillin-tazobactam (or meropenem for more resistant organisms) provides broad-spectrum gram-negative and anaerobic coverage as monotherapy, eliminating the need for both gentamicin and metronidazole while avoiding the PMF-dependent limitation and the toxicity burden of aminoglycosides; alternatively, ceftriaxone plus metronidazole covers gram-negative aerobes and anaerobes with a favorable safety profile.
• D) Continue the current gentamicin plus metronidazole regimen without changes; the PMF limitation of gentamicin in anaerobic environments applies only to obligate anaerobes such as B. fragilis, and the gram-negative aerobic organisms (E. coli) maintain aerobic metabolism even in mixed peritoneal infections because they generate their own microaerobic environment within the peritoneal exudate that sustains their electron transport chain activity.
• E) Discontinue gentamicin immediately due to toxicity concerns and replace with azithromycin; azithromycin covers gram-negative enteric organisms through 50S ribosomal inhibition and achieves high peritoneal tissue concentrations through its large volume of distribution; continue metronidazole for anaerobic coverage; the azithromycin-metronidazole combination provides complete peritoneal coverage without aminoglycoside toxicity risk.